AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase II clinical study titled ‘A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib With Amivantamab as First-line Treatment in Participants With Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA)’. The study aims to assess the safety and efficacy of combining Osimertinib and Amivantamab as a first-line treatment for patients with specific mutations in non-small cell lung cancer (NSCLC).
The study tests two drugs: Osimertinib, an oral tablet taken daily, and Amivantamab, an intravenous infusion administered in cycles. These interventions target mutations in the epidermal growth factor receptor (EGFR) to manage advanced or metastatic NSCLC.
This open-label, single-group study focuses on treatment, with no masking involved. Participants receive the drug combination until disease progression or discontinuation criteria are met, with regular follow-ups to monitor outcomes.
The study began on July 18, 2023, with primary completion and estimated completion set for June 24, 2025. These dates are crucial for tracking the study’s progress and potential market entry of the treatment.
The update on this study could influence AstraZeneca’s stock performance positively, given the potential for a new treatment option in the competitive NSCLC market. Investors may view this as a strategic move to strengthen AstraZeneca’s oncology portfolio.
The study is ongoing, with further details available on the ClinicalTrials portal.